Richard Reeve started his career in Clinical Research in 1991 at Pfizer’s European Headquarters as a Clinical Data Manager before moving into Clinical Operations. He subsequently expanded his role to develop the European Clinical Operations team for DuPont Pharmaceuticals before moving into a Clinical Quality Assurance role. Following a move to the United States in 2006, Richard assumed responsibility for the global GCP audit program at Elan Pharmaceuticals. Richard had subsequent roles as Head of Quality at Cerexa and then Endo Pharmaceuticals. In 2017 he established RPR Consulting, Inc., using his experience to develop and re-engineer GCP quality systems and help sponsors prepare for and successfully complete regulatory inspections directed by the FDA and EMA. Since March 2021 Richard has been President of 2Richards, Inc.

Richard Gill founded and managed a UK-based CRO for 11 years. In 1999, he relocated to the United States and worked for Quintiles Transnational to reengineer their global analytical laboratory and IVR businesses. He was then appointed head of the Global Quality Management Group, gaining his Six Sigma Black Belt in 2001. In 2002, Richard followed his growing interest in quality issues to Elan Pharmaceuticals as VP and Global Head of Quality and Process and, subsequently, at Chiron Corporation in 2005 as VP of Compliance and Process Improvement. Richard set up RCG Consulting, Inc. in 2007, drawing on his 35 years of experience to help companies manage GCP compliance risk and prepare for and successfully manage FDA and EMA pre‑approval inspections. He held interim roles as VP of Quality at Elan in 2008 and SVP of Quality at Cubist in 2014.